Moderna, Inc.
572 articles with Moderna, Inc.
-
The U.S. FDA is expected to give the go-ahead for Pfizer and BioNTech’s COVID-19 vaccine for adolescents ages 12 and older within the week.
-
Please check out the biopharma industry's COVID-19 stories that are trending for May 4, 2021.
-
Moderna Announces Supply Agreement with Gavi for up to 500 Million Doses of COVID-19 Vaccine Moderna for COVAX To Help End COVID-19 Pandemic in Lowest Income Countries
5/3/2021
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced an agreement with Gavi, the Vaccine Alliance to supply up to 500 million doses of the COVID-19 Vaccine Moderna, including an initial 34 million doses to be delivered in the fourth quarter of 2021.
-
BioSpace takes an in-depth look at the Top 25 of Q1.
-
Moderna Announces Emergency Use Listing Granted by the World Health Organization for its COVID-19 Vaccine
4/30/2021
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that the World Health Organization has issued Emergency Use Listing for its COVID-19 vaccine to prevent COVID-19 in individuals 18 years of age and older.
-
Moderna Announces Additional Investments to Increase Global Supply for COVID-19 Vaccine to up to 3 Billion Doses in 2022
4/29/2021
Supply also expected to benefit from shift to lower-dose product mix, including potential variant booster vaccines and pediatric primary vaccine doses
-
Moderna, one of three companies to have a COVID-19 vaccine authorized in the U.S., isn’t resting on its accomplishments but is instead working to scale up production further and improve on its vaccine.
-
DNA Script Partners with Moderna to Develop On-Demand Vaccines and Therapeutics for DARPA
4/27/2021
Company will receive up to $5 Million in grant funds from DARPA as part of the agency's Nucleic Acids On-Demand World-Wide Program to plan for and prevent the next viral pandemic
-
2021 COVID-19 News: COVID-19 Possible Spread in Vehicles, US to Share AZ's COVID-19 Vaccine Globa...
4/27/2021
Please check out the biopharma industry's COVID-19 stories that are trending for April 27, 2021. -
Sanofi to help manufacture Moderna COVID-19 vaccine, supporting global supply demands
4/26/2021
- Sanofi is the only company to leverage its manufacturing capacity and expertise to support three different COVID-19 vaccines to support the global supply of vaccines and help address the pandemic - Sanofi to manufacture up to 200 million doses of Moderna's vaccine in the U.S. starting in September 2021
-
Moderna Announces Agreement with Sanofi for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.
4/26/2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has entered into an agreement with Sanofi (Nasdaq: SNY) for fill/finish sterile manufacturing services and supply packaging for up to 200 million doses of the Moderna COVID-19 Vaccine in the U.S. beginning in September 2021
-
At the end of February, the U.S. was averaging 65,686 new COVID-19 cases per day. Fast-forward two months and that number is nearly identical at 64,814.
-
With the U.S. Food and Drug Administration’s vaccines advisory committee meeting being held today to discuss the Johnson & Johnson vaccine and blood clotting, there’s even more interest in what’s going on in the pandemic than usual. Here’s a look at some of the top stories.
-
Executives at pharmaceutical companies are known for receiving large salaries. When bonuses and stock options are factored into the picture, their annual compensation can jump into the range of tens of millions of dollars, like Pfizer’s Albert Bourla, Alex Gorsky from Johnson & Johnson, and Astra...
-
Shareholders have been pleased with the company’s mRNA vaccine, but some, including the company’s cofounder, are cashing in on their stock gains.
-
Moderna Announces New Supply Agreement with Israel for 2022
4/20/2021
First firm order reached with the Company for 2022 supply Israel also retains an option to purchase doses of variant-specific vaccine booster candidate, pending regulatory approval
-
COVID-19 News: Researchers Discover a New Variant, Antiviral Shows Promise in Hamsters and More
4/20/2021
Please check out the biopharma industry's COVID-19 stories that are trending for April 20, 2021. -
Moderna to Report First Quarter Financial Results on Thursday, May 6, 2021
4/16/2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 6, 2021 to reports its first quarter 2021 financial results, and provide a corporate update.
-
It has been reported that Johnson & Johnson contacted Pfizer, Moderna, and AstraZeneca about investigating the clots and to “speak with one voice about safety.” However, both Pfizer and Modera declined, indicating that their vaccines were not associated with blood clots.
-
Moderna Announces Clinical Progress from its Industry-Leading mRNA Vaccine Franchise and Continues Investments to Accelerate Pipeline Development
4/14/2021
CMV 7-month data shows all GMT measures at or above CMV seropositive baselines; pivotal Phase 3 study of at least 8,000 participants expected to begin in 2021